Serina Therapeutics (SER) Receivables (2017 - 2024)

Serina Therapeutics has disclosed Receivables across 8 years of filings, most recently posting -$98000.0 for Q1 2024.

• In Q1 2024, Receivables fell 22.5% year-over-year to -$98000.0; the TTM figure through Mar 2024 stood at -$98000.0 (down 22.5% YoY), while the FY2023 annual figure was $611000.0, up 15175.0% from the prior year.
• Receivables came in at -$98000.0 for Q1 2024 at Serina Therapeutics, down from $232000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $728000.0 in Q3 2023 to a low of -$190000.0 in Q2 2023.
• Average Receivables over 5 years is $117812.5, with a median of $24500.0 recorded in 2021.
• The largest YoY upside for Receivables was 72700.0% in 2023 against a maximum downside of 1683.33% in 2023.
• Over 5 years, Receivables stood at $326000.0 in 2020, then slumped by 92.33% to $25000.0 in 2021, then sank by 84.0% to $4000.0 in 2022, then jumped by 5700.0% to $232000.0 in 2023, then sank by 142.24% to -$98000.0 in 2024.
• Per Business Quant data, the three most recent Receivables figures were -$98000.0 in Q1 2024, $232000.0 in Q4 2023, and $728000.0 in Q3 2023.